- Recommendation ID
- NG230/01
- Question
Molecular tests: In fine-needle aspiration cytology (FNAC) samples that are adequate but cannot differentiate between benign and malignant samples, what is the clinical and cost effectiveness of molecular testing for thyroid cancer?
- Any explanatory notes
(if applicable) For a short explanation of why the committee made this recommendation for research, see the rationale section on management and further sampling after initial FNAC.
Full details of the evidence and the committee's discussion are in evidence review F: molecular testing.
Source guidance details
- Comes from guidance
- Thyroid cancer: assessment and management
- Number
- NG230
- Date issued
- December 2022
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 31/12/2022 |